Premium
Surface CD14 positivity in B‐cell chronic lymphocytic leukaemia is related to clinical outcome
Author(s) -
Callea Vincenzo,
Morabito Fortunato,
Oliva Bianca Maria,
Stelitano Caterina,
Levato Domenico,
Dattilo Angela,
Gangemi Francesca,
Iorfida Antonella,
Iacopino Pasquale,
Nobile Francesco,
Molica Stefano,
Brugiatelli Maura
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01695.x
Subject(s) - medicine , cd14 , univariate analysis , gastroenterology , proportional hazards model , multivariate analysis , oncology , immunology , receptor
The aberrant expression of the myelomonocytic antigen CD14 was investigated in 128 untreated patients diagnosed with B‐cell chronic lymphocytic leukaemia (B‐CLL). A cut‐off value of 5 × 10 9 /l CD14‐positive cells was chosen for statistical analysis because it showed the best discriminating power among patients with different clinical features. 56 cases had a CD14 + cell count >5 × 10 9 /l. A significant correlation was found between Rai and Binet stages and total tumour mass (TTM) score on one hand, and the absolute CD14 + cell cut‐off, on the other. This relationship was more evident in Rai 0–II and Binet A–B stages, where a CD14 + cell count >5 × 10 9 /l was preferentially distributed among patients with a higher tumoral mass. In univariate analysis the survival probability at 5 and 10 years showed a significant correlation with Rai and Binet stages, TTM score, CD14 + absolute cell count and median age. The median overall survival (OS) was 63 months for patients with a CD14 + cell count >5 × 10 9 /l and 136 months for those with a CD14 + cell count < 5 × 10 9 /l. In the multivariate Cox regression model, Rai stage, age and CD14 + cell count were independent significant factors for the prediction of OS. Finally, when the same analysis was restricted to Rai stages 0–II, CD14 + cell count was the only significant independent parameter influencing OS, with a relative death risk of 3.8. In conclusion, these data reveal that CD14 + represents an important marker for predicting OS in B‐CLL patients and, therefore, we suggest that it should be included in the immunological characterization of B‐CLL.